Clinical trials: Locally Advanced Solid Tumor
Gastrointestinal Tumors, Solid Tumors
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M24D1 for Injection in patients with locally advanced…
- Trial name
- NCT07279428
- Testing
- BL-M24D1
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with…
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
- Trial name
- BetaBart (NCT07189871)
- Testing
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Radiopharm Theranostics, Ltd
Locally Advanced or Metastatic Solid Tumors
Assessment of Safety and Preliminary Clinical Efficacy with BAT6005 in Advanced Malignant Solid Tumors
This research design for center, increasing openness, dose and dose extension phase I clinical trials, research the main evaluation BAT6005 injection single drug in patients with advanced malignant solid tumors in the safety…
- Trial name
- NCT05116709
- Testing
- BAT6005 injection
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Bio-Thera Solutions
Solid Tumor, Advanced Cancer
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the safety and tolerability of DS-1055a in participants with relapsed or refractory locally advanced or metastatic solid tumors for which no standard treatment is available.
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Solid Tumor
- Trial name
- NCT04419532
- Testing
- DS-1055a
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Solid Tumors
A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors
A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors
- Trial name
- NCT06826313
- Testing
- VRT106
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.
Advanced Breast Cancer, Other Solid Tumors
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)
An investigational study to determine the safety/tolerability, and efficacy of a notch signaling pathway inhibitor in patients with metastatic or locally advanced breast cancer and other advanced solid tumors.
- Trial name
- NCT00106145
- Testing
- Comparator: MK0752, Notch Inhibitor, Comparator: MK0752, Notch Inhibitor - 450 mg, Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off
- Volunteers
- 103 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor
PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors
HS-10241 is a highly potent and selective small molecule inhibitor of c-Met kinase. In preclinical studies, it demonstrated strong activity against c-Met kinase in vitro and in vivo, and inhibited tumor cell growth.
- Trial name
- NCT04477057
- Testing
- HS-10241
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Neoplasms
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06664178 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02122146
- Testing
- PF-06664178
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pfizer
Advanced Melanoma and Normal or Impaired, Advanced Melanoma
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
This study is a first-in-human, open-label, nonrandomized, single center Phase 1 dose-escalation study to assess the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of AB821…
- Trial name
- Asher-BioAB821 (NCT07027488)
- Testing
- AB821
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yale University
Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination…
- Conditions
- Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Trial name
- KAT6 (NCT04606446)
- Testing
- PF-07248144, Fulvestrant, Letrozole
- Where
- 43 sites in United States, Australia and 3 more
- Volunteers
- 320 people
- Sponsor
- Pfizer
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is…
- Trial name
- ON-TRK (NCT04142437)
- Testing
- larotrectinib(Vitrakvi, BAY2757556)
- Where
- 47 sites in United States, Argentina and 13 more
- Volunteers
- 54 people
- Sponsor
- Bayer
Melanoma, Solid Tumors
A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid Tumors
This Phase Ib/II study is a clinical study to explore the efficacy and safety of BL-M08D1 for injection in patients with locally advanced or metastatic melanoma and other solid tumors.
- Trial name
- NCT07841925
- Testing
- BL-M08D1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Esophageal Cancer, Gastric Cancer
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in…
- Conditions
- Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT06500052
- Testing
- BL-M17D1
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Solid Tumor Malignancies
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
This protocol will examine the safety of intratumoral administration of Clostridium Novyi-NT spores in patients with treatment-refractory solid tumor malignancies. This investigational study will measure anti-tumor activity of C.
- Trial name
- NCT01924689
- Testing
- Clostridium novyi-NT spores
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- BioMed Valley Discoveries, Inc
Breast Cancer, Gastric/Gastroesophageal Junction Cancer
KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer
This is an open-label, phase 1 dose-escalation study of KN026 in subjects with HER2 positive advanced breast and Gastric Cancer. The standard "3 + 3" design was used for dose escalation.
- Trial name
- NCT03847168
- Testing
- KN026
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced or Metastatic Solid Tumors
Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human, open label, multicenter, dose escalation study of RXDX-106 in patients with locally advanced or metastatic solid tumors, who have no available therapy likely to convey clinical benefit.
- Trial name
- TITAN (NCT03454243)
- Testing
- RXDX-106
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors
TrasGEX™: Phase 1 Study in Cancer Patients
This was a prospective, open label, multicenter study evaluating the safety, tolerability and pharmacokinetics of TrasGEX™ after intravenous administration in patients with HER-2 positive cancers.
- Trial name
- NCT01409343
- Testing
- TrasGEX™
- Where
- 5 sites in Austria, Germany and 2 more
- Volunteers
- 37 people
- Sponsor
- Glycotope GmbH
Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis
This clinical trial examines the acceptability and effect of a parenting support intervention for families coping with solid tumor that has spread to other places in the body (metastatic) or has come back (recurrent).
- Trial name
- NCT05059678
- Testing
- Best Practice, Educational Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors
This study is an open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of IBR854 cell injection in patients with unresectable, locally advanced, or metastatic solid tumors.
- Trial name
- NCT06001684
- Testing
- IBR854 Cell Injection
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Imbioray (Hangzhou) Biomedicine Co., Ltd.